A multicentre, phase III, double-blind, randomised clinical trial to assess the efficacy and safety of LPRI-424 (dienogest 2.00 mg / ethinyl estradiol 0.02 mg) in the treatment of polycystic ovary syndrome (PCOS) versus placebo during 9 cycles
Latest Information Update: 06 Jun 2024
At a glance
- Drugs Ethinylestradiol/dienogest (Primary)
- Indications Hirsutism
- Focus Registrational; Therapeutic Use
- Sponsors Chemo Research, S.L.
Most Recent Events
- 05 Jun 2024 This trial has been completed in Czech Republic (Global end date: 5 Dec 2023).
- 11 Feb 2024 This trial has been completed in Poland (Global end date: 5 Dec 2023).
- 26 Jan 2024 This trial has been completed in Lithuania and Slovakia (End Date: 05 Dec 2023), according to European Clinical Trials Database record.